Information Provided By:
Fly News Breaks for March 8, 2019
INSY
Mar 8, 2019 | 06:34 EDT
Pressure on Subsys was once again a central theme in Insys Therapeutics' Q4 results, Piper Jaffray analyst David Amsellem tells investors in a post-earnings research note. The analyst says that given the challenging dynamics associated with Subsys, he has a difficult time envisioning a buyer emerging for the product. Amsellem continues to believe there is downside risk associated with Insys Therapeutics shares. He reiterates an Underweight rating on the name with a $4 price target.
News For INSY From the Last 2 Days
There are no results for your query INSY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.